A

argenx SE
D

ARGX

643.25
USD
-3.27
(-0.51%)
مفتوح الان
حجم التداول
5,304
الربح لكل سهم
7
العائد الربحي
-
P/E
-825
حجم السوق
38,463,952,607
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -3.600
    (-2.09%)
    169.170 USD
    BMY
    BMY
    -0.240
    (-0.42%)
    56.810 USD
    GSK
    GSK
    -0.140
    (-0.41%)
    33.640 USD
    LLY
    LLY
    12.68
    (1.71%)
    755.05 USD
    NVS
    NVS
    -0.880
    (-0.88%)
    98.880 USD
    PFE
    PFE
    -0.336
    (-1.26%)
    26.275 USD
    REGN
    REGN
    0.23
    (0.03%)
    687.55 USD
    SNY
    SNY
    -0.420
    (-0.81%)
    51.280 USD
    U
    UCB
    -0.530
    (-1.59%)
    32.750 USD
    المزيد
الأخبار
المقالات

العنوان: argenx SE

القطاع: Healthcare
الصناعة: Biotechnology
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.